SCHEDULE: FMR LLC Reports 3.6% Stake in Immunocore Holdings PLC

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 3.6% in Immunocore Holdings PLC as of September 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, collectively beneficially own 1,736,979 shares of Immunocore Holdings PLC common stock.
• This ownership stake represents 3.6% of the class of securities.
• The filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership.
• The reporting persons are classified as investment advisers (IA) and banks (BK) through their affiliated entities.
• The filing confirms that no single other person's interest in the common stock exceeds five percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes without significant new financial or strategic information.

Positives

• FMR LLC and Abigail P. Johnson's investment indicates confidence in Immunocore Holdings PLC.
• The clear reporting of ownership provides transparency to the market.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Immunocore Holdings PLC.
• The increase in ownership by FMR LLC could be interpreted as a precursor to further market activity, which may introduce volatility.

Risks

• Potential for increased market influence by FMR LLC and its affiliates.
• The filing does not offer insights into Immunocore's operational performance or future prospects, leaving investors to seek this information elsewhere.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Immunocore Holdings PLC's future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported in Schedule 13G filings, is common in the biotechnology and pharmaceutical sectors, where companies like Immunocore operate. Such filings often precede or follow other significant corporate events.

Stakeholder Impact

• Shareholders: Increased institutional interest may signal positive sentiment, but the lack of new company performance data limits immediate impact.
• Management: The filing provides transparency regarding significant ownership, which is a standard disclosure requirement.

Next Steps

• Continued monitoring of FMR LLC's and Abigail P. Johnson's ownership stake in Immunocore Holdings PLC.

Key Dates

Keywords

Immunocore Holdings PLC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock